Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

Item

http://www.wikidata.org/entity/Q42563983

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@en

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@nl

type

Item

label

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@en

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@nl

prefLabel

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@en

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@nl

P1476

Visual Hallucinations Associated with High Posaconazole Concentrations in Serum.

@en

P2093

Donald C Sheppard

http://www.w3.org/2001/XMLSchema#string

Leighanne O Parkes

http://www.w3.org/2001/XMLSchema#string

P2860

Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain

Antifungal Azoles: Structural Insights into Undesired Tight Binding to Cholesterol-Metabolizing CYP46A1

Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease.

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.

Voriconazole: a new triazole antifungal agent.

Voriconazole, an antifungal triazol that causes visual side effects, is an inhibitor of TRPM1 and TRPM3 channels

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies.

Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.

Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.

P304

1170-1171

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.02739-15

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matthew P. Cheng

P577

2015-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26643343

http://www.w3.org/2001/XMLSchema#string

P921

hallucination

P932

4750663

http://www.w3.org/2001/XMLSchema#string